SPONSOR
GenomeFrontier Therapeutics TW Co., Ltd.
Total Trials
1
Recruiting
1
Phases
Phase 1
Conditions studied: Diffuse Large B Cell Lymphoma RelapsedDiffuse Large B Cell Lymphoma RefractoryFollicular Lymphoma ( FL)Primary Mediastinal Large B-Cell Lymphoma-RefractoryPrimary Mediastinal Large B-Cell Lymphoma-RecurrentHigh-grade B-cell Lymphoma (HGBCL)
GenomeFrontier Therapeutics TW Co., Ltd. is a clinical research sponsor with 1 registered studies on ClinicalTrials.gov, of which 1 are actively recruiting participants. Research covers conditions including Diffuse Large B Cell Lymphoma Relapsed, Diffuse Large B Cell Lymphoma Refractory, Follicular Lymphoma ( FL), Primary Mediastinal Large B-Cell Lymphoma-Refractory.
The trial portfolio spans Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — GenomeFrontier Therapeutics TW Co., Ltd.
How many clinical trials has GenomeFrontier Therapeutics TW Co., Ltd. sponsored?
ClinicalMetric currently tracks 1 clinical trials sponsored by GenomeFrontier Therapeutics TW Co., Ltd., of which 1 are actively recruiting participants. These trials cover conditions including Diffuse Large B Cell Lymphoma Relapsed, Diffuse Large B Cell Lymphoma Refractory, Follicular Lymphoma ( FL). Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does GenomeFrontier Therapeutics TW Co., Ltd. research focus on?
GenomeFrontier Therapeutics TW Co., Ltd. clinical trials span Diffuse Large B Cell Lymphoma Relapsed, Diffuse Large B Cell Lymphoma Refractory, Follicular Lymphoma ( FL), Primary Mediastinal Large B-Cell Lymphoma-Refractory, Primary Mediastinal Large B-Cell Lymphoma-Recurrent, and additional conditions. The research pipeline includes Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a GenomeFrontier Therapeutics TW Co., Ltd. clinical trial?
To participate in a GenomeFrontier Therapeutics TW Co., Ltd. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all GenomeFrontier Therapeutics TW Co., Ltd. trials with current recruitment status updated daily.
Clinical Trials by GenomeFrontier Therapeutics TW Co., Ltd.
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology